Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV, ...

A fringe far-right populist party in Japan was one of the biggest winners in the weekend’s upper house election. Sanseito ...

Billionaire Mike Bloomberg slammed President Donald Trump‘s Secretary of Health and Human Services Robert F. Kennedy, Jr. in ...

Learn how olive oil's anti-inflammatory components helped create a less painful and longer lasting mRNA vaccine, and showed ...

Sanofi agreed to buy UK vaccine developer Vicebio Ltd. for as much as $1.6 billion, as it seeks to expand in respiratory ...

Sanofi is buying Vicebio for more than $1 billion, picking up an experimental vaccine targeting RSV and another respiratory bug.

Sanofi is buying U.K. biotechnology company Vicebio for up to $1.6 billion in a deal that seeks to strengthen the French drugmaker's portfolio of respiratory vaccines and leave pipeline setbacks ...

The loonies have new reasons to follow their conspiracy theories, only this time, Trump is on the wrong side. Uh oh.

The approach, which mimics how the body responds to a virus, could pave the way for a universal cancer vaccine.